Yarrow Bioscience, Inc. 10-K

ITEM 5 - MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Our common stock was previously listed on Nasdaq under the symbol “MNLO” since January 24, 2018 until it changed to "VYNE" in connection with the corporate name change on September 4, 2020. Prior to January 24, 2018, there was no public trading market for our common stock. On February 10, 2021, our Board of Directors approved a one-for-four reverse stock split of our outstanding shares of common stock. The reverse stock split was effected on February 12, 2021 at 5:00 p.m. Eastern time. At the effective time, every four issued and outstanding shares of our common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company’s transfer agent in an amount equal to such stockholder’s respective pro rata shares of the total net proceeds from the Company’s transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of our common stock was also reduced on a one-for-four basis, from 300 million to 75 million. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan. Holders of Common Stock 72 Table of Contents As of February 25, 2020, there were approximately 8 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name. ITEM 6 - SELECTED FINANCIAL DATA Removing and reserving Item 6. 73 Table of Contents